Skip to main content
Premium Trial:

Request an Annual Quote

Sophia Genetics Gets CE-IVD Mark for DDM Platform's Analytics

NEW YORK – Sophia Genetics said that it has received CE-IVD marking for analytics functionality of its core Sophia Data Driven Medicine (DDM) software platform. The Swiss-American firm made the announcement Tuesday at the European Society of Human Genetics conference in Vienna.

The new CE-IVD marking covers two specific applications, namely the Sophia DDM Dx Homologous Recombination Deficiency (HRD) Solution and RNAtarget Oncology Solution. Sophia previously earned CE marks for its Hereditary Cancer Solution, for genetic testing of familial Mediterranean fever and hypercholesterolemia, and for its next-generation sequencing bioinformatics pipeline.

The company said that the new certification means that Sophia DDM is now "IVD-ready to support all applications and modules designed for diagnostic purposes" in the EU and other countries that recognize the CE mark.

"The CE-IVD certification for these IVD applications is a milestone that reflects the quality and reliability of our Sophia DDM platform," Cofounder and CEO Jurgi Camblong said in a statement. "This will help us meet the needs of our healthcare partners in the EU who want to implement Sophia Genetics' proprietary algorithms for clinical use."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.